Viviany R Taqueti1, Brendan M Everett1, Venkatesh L Murthy1, Mariya Gaber1, Courtney R Foster1, Jon Hainer1, Ron Blankstein1, Sharmila Dorbala1, Marcelo F Di Carli2. 1. From the Noninvasive Cardiovascular Imaging Program, Heart and Vascular Institute, Division of Cardiovascular Medicine, Department of Medicine, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (V.R.T., M.G., C.R.F., J.H., R.B., S.D., M.F.D.C.); Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (B.M.E.); and Divisions of Nuclear Medicine, Cardiothoracic Imaging, and Cardiovascular Medicine, Departments of Medicine and Radiology, University of Michigan, Ann Arbor (V.L.M.). 2. From the Noninvasive Cardiovascular Imaging Program, Heart and Vascular Institute, Division of Cardiovascular Medicine, Department of Medicine, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (V.R.T., M.G., C.R.F., J.H., R.B., S.D., M.F.D.C.); Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (B.M.E.); and Divisions of Nuclear Medicine, Cardiothoracic Imaging, and Cardiovascular Medicine, Departments of Medicine and Radiology, University of Michigan, Ann Arbor (V.L.M.). mdicarli@partners.org.
Abstract
BACKGROUND: Minimally elevated serum cardiac troponin reflects myocardial injury and is associated with increased mortality, even absent coronary artery disease (CAD). We sought to investigate the relationship between low-level troponin elevation and impaired coronary flow reserve (CFR), an integrated measure of coronary vasomotor function, and to assess their contributions to adverse outcomes in patients without overt CAD. METHODS AND RESULTS: Consecutive patients (n=761) undergoing evaluation for suspected CAD with troponin before stress myocardial perfusion positron emission tomography were followed up (median, 2.8 years) for major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, or late revascularization. Patients with flow-limiting CAD, left ventricular ejection fraction <40%, or revascularization within 60 days of imaging were excluded. CFR was quantified from stress/rest myocardial blood flow with the use of positron emission tomography. Compared with patients with negative troponin, those with at least 1 positive troponin (n=97) had higher pretest clinical scores, more renal dysfunction, and lower left ventricular ejection fraction and CFR. In adjusted analysis, impaired CFR remained independently associated with positive troponin (odds ratio, 2.18; 95% confidence interval, 1.37-3.47; P=0.001), and both impaired CFR and positive troponin were independently associated with major adverse cardiovascular events (hazard ratio, 2.25; 95% confidence interval, 1.31-3.86; P=0.003; and hazard ratio, 2.42; 95% confidence interval, 1.34-4.40; P=0.004, respectively). Impaired CFR and positive troponin identified patients at highest risk of major adverse cardiovascular events (log-rank P<0.0001), with a significant interaction (P<0.007) seen between CFR and troponin. CONCLUSIONS: In patients without overt CAD, impaired CFR was independently associated with minimally elevated troponin and major adverse cardiovascular events. Impaired CFR, here reflecting microvascular dysfunction, modified the effect of a positive troponin on adverse outcomes.
BACKGROUND: Minimally elevated serum cardiac troponin reflects myocardial injury and is associated with increased mortality, even absent coronary artery disease (CAD). We sought to investigate the relationship between low-level troponin elevation and impaired coronary flow reserve (CFR), an integrated measure of coronary vasomotor function, and to assess their contributions to adverse outcomes in patients without overt CAD. METHODS AND RESULTS: Consecutive patients (n=761) undergoing evaluation for suspected CAD with troponin before stress myocardial perfusion positron emission tomography were followed up (median, 2.8 years) for major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, or late revascularization. Patients with flow-limiting CAD, left ventricular ejection fraction <40%, or revascularization within 60 days of imaging were excluded. CFR was quantified from stress/rest myocardial blood flow with the use of positron emission tomography. Compared with patients with negative troponin, those with at least 1 positive troponin (n=97) had higher pretest clinical scores, more renal dysfunction, and lower left ventricular ejection fraction and CFR. In adjusted analysis, impaired CFR remained independently associated with positive troponin (odds ratio, 2.18; 95% confidence interval, 1.37-3.47; P=0.001), and both impaired CFR and positive troponin were independently associated with major adverse cardiovascular events (hazard ratio, 2.25; 95% confidence interval, 1.31-3.86; P=0.003; and hazard ratio, 2.42; 95% confidence interval, 1.34-4.40; P=0.004, respectively). Impaired CFR and positive troponin identified patients at highest risk of major adverse cardiovascular events (log-rank P<0.0001), with a significant interaction (P<0.007) seen between CFR and troponin. CONCLUSIONS: In patients without overt CAD, impaired CFR was independently associated with minimally elevated troponin and major adverse cardiovascular events. Impaired CFR, here reflecting microvascular dysfunction, modified the effect of a positive troponin on adverse outcomes.
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Mariya Gaber; Sharmila Dorbala; David M Charytan; Ron Blankstein; Marcelo F Di Carli Journal: JACC Cardiovasc Imaging Date: 2012-10
Authors: Torbjørn Omland; Marc A Pfeffer; Scott D Solomon; James A de Lemos; Helge Røsjø; Jūratė Šaltytė Benth; Aldo Maggioni; Michael J Domanski; Jean L Rouleau; Marc S Sabatine; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2013-02-13 Impact factor: 24.094
Authors: Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Mariya Gaber; Jon Hainer; Josh Klein; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Circulation Date: 2012-08-23 Impact factor: 29.690
Authors: Lauren A Baldassarre; Subha V Raman; James K Min; Jennifer H Mieres; Martha Gulati; Nanette K Wenger; Thomas H Marwick; Chiara Bucciarelli-Ducci; C Noel Bairey Merz; Dipti Itchhaporia; Keith C Ferdinand; Carl J Pepine; Mary Norine Walsh; Jagat Narula; Leslee J Shaw Journal: JACC Cardiovasc Imaging Date: 2016-04
Authors: Navkaranbir S Bajaj; Michael T Osborne; Ankur Gupta; Ali Tavakkoli; Paco E Bravo; Tomas Vita; Courtney F Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Deepak L Bhatt; Marcelo F Di Carli; Viviany R Taqueti Journal: J Am Coll Cardiol Date: 2018-08-14 Impact factor: 24.094
Authors: Viviany R Taqueti; Scott D Solomon; Amil M Shah; Akshay S Desai; John D Groarke; Michael T Osborne; Jon Hainer; Courtney F Bibbo; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Eur Heart J Date: 2018-03-07 Impact factor: 29.983
Authors: Johnathan D Tune; Adam G Goodwill; Alexander M Kiel; Hana E Baker; Shawn B Bender; Daphne Merkus; Dirk J Duncker Journal: Am J Physiol Heart Circ Physiol Date: 2019-11-08 Impact factor: 4.733
Authors: Viviany R Taqueti; Leslee J Shaw; Nancy R Cook; Venkatesh L Murthy; Nishant R Shah; Courtney R Foster; Jon Hainer; Ron Blankstein; Sharmila Dorbala; Marcelo F Di Carli Journal: Circulation Date: 2016-11-14 Impact factor: 29.690
Authors: Ankur Gupta; Viviany R Taqueti; Tim P van de Hoef; Navkaranbir S Bajaj; Paco E Bravo; Venkatesh L Murthy; Michael T Osborne; Sara B Seidelmann; Tomas Vita; Courtney F Bibbo; Meagan Harrington; Jon Hainer; Ornella Rimoldi; Sharmila Dorbala; Deepak L Bhatt; Ron Blankstein; Paolo G Camici; Marcelo F Di Carli Journal: Circulation Date: 2017-09-01 Impact factor: 29.690